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Door to PVAD insertion (minutes) 242528.9
Prior insertion of intra-aortic balloon pump 8(88.9)Multi-vessel disease 3(42.9)Mean Qp:Qs ratio 2.51.6
VSD size (cm) 1.91.2
Right atrial oxygen saturation 5315.5
Pulmonary artery oxygen saturation 824
Ischemic limb 2(22.2)Stroke 1(11.1)Renal replacement therapy 4(44.4)CONCLUSIONS In this single center PVAD series, use of TandemHeart
in postinfarction CS and VSD may improve survival. It provides sig-
niﬁcant ventricular unloading with improved organ perfusion.
Further research into the optimal duration of ventricular support and
timing of repair is warranted.
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BACKGROUND Cardiogenic shock (CGS) is associated with increased
mortality despite advancements in treatment. Although CGS compli-
cates around 10% of acute myocardial infarction, it accounts for
almost 90% of mortality in this patient sub-group. The purpose of this
study was to determine the predictors of 30-day mortality and out-
comes in patients who received percutaneous left ventricular support
with an Impella device.
METHODS In this retrospective study, we collected data on all pa-
tients who required impella support device for cardiogenic shock.
Data on in-hospital mortality and 30 day mortality was also recorded.
RESULTS This single-center registry retrospectively included 41 pa-
tients (58.5+16.4 years; 68.2% male) with CGS receiving Impella left
ventricular assist device for temporary circulatory support. The de-
mographic characteristics are shown in table 1. The primary end-point
was mortality at 30 days. Secondary endpoints included change in
plasma lactate levels, early major adverse cardiac and
cerebrovascular events and complications. Thirty day mortality was
48.8% in the study population. Successful implantation of Impella
was performed in all patients. Following the implantation of
Impella, lactate levels decreased from 3.9+3.7 mmol/L to 1.8+2.06
mmol/L at 48 hours. Major bleeding at access site requiring blood
transfusion occurred in 4 (9.8%) patients. Hemolysis occurred in 1
patient and no incidence of pericardial tamponade. Lactate
level>3.8 mmol/L at admission was identiﬁed as a predictor of 30-
day mortality.Table 1. Baseline Characteristics (n¼41)Hypertension, n (%) 28 (68.2)Diabetes mellitus, n (%) 18 (43.9)Hypercholesterolemia, n (%) 25 (60.1)Previous myocardial infarction, n (%) 16 (39)Previous coronary artery bypass grafting, n (%) 6 (14.6)Stroke, n (%) 8 (19.5)Chronic obstructive pulmonary disease 2 (4.9)Inotropes and vasopressors, n (%) 25 (61)Mechanical ventilation, n (%) 17 (41.5)CPR within 72 hours before device implantation,
n (%)6 (14.6)Intra-aortic counterpulsation, n (%) 13 (31.7)Mean blood pressure, mm Hg SD 74.419.5
Ejection fraction  SD 0.260.09
Lactate, mmol/L SD 3.93.7
Creatinine, mmol/LSD 176.1150.4CONCLUSIONS In this study, we showed that temporary mechanical
circulatory support with Impella is feasible and results in a reduction
of lactate levels. Higher lactate (>3.8mmol/L) levels predicts 30-day
mortality. This reﬂects hemodynamic instability and worse outcome
in these selected patients. Therefore, early institution of Impella in
these patients may improve outcome. Randomized controlled trials
are required to further evaluate the efﬁcacy of Impella left ventricular
assist device in CGS.
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